Table 4.
Maternal geometric mean antibody concentrations and ratios to baseline
| HIV-infected, low CD4 cell count | HIV-infected, high CD4 cell count | HIV-uninfected | Low CD4vshigh CD4 | Low CD4vsHIV-uninfected | High CD4vsHIV-uninfected | ||
|---|---|---|---|---|---|---|---|
| Serotype Ia | |||||||
| Data available, n | 74 | 75 | 77 | .. | .. | .. | |
| Geometric mean antibody concentration (μg/mL) | |||||||
| Day 1 pre-vaccination | 0·24 (0·19–0·30) | 0·25 (0·20–0·32) | 0·38 (0·30–0·48) | p=0·709 | p=0·007 | p=0·019 | |
| Day 15 post-vaccination | 2·62 (1·64–4·17) | 2·95 (1·86–4·69) | 5·61 (3·56–8·84) | p=0·713 | p=0·023 | p=0·053 | |
| Day 31 post-vaccination | 2·68 (1·74–4·10) | 3·26 (2·14–4·98) | 6·63 (4·37–10) | p=0·513 | p=0·003 | p=0·020 | |
| Delivery | 2·22 (1·50–3·29) | 2·69 (1·82–3·98) | 4·49 (3·06–6·60) | p=0·493 | p=0·013 | p=0·067 | |
| Geometric mean ratio to day 1 | |||||||
| Day 15 | 8·36 (5·27–13) | 9·54 (6·02–15) | 19 (12–30) | p=0·690 | p=0·011 | p=0·032 | |
| Day 31 | 8·55 (5·60–13) | 11 (6·91–16) | 23 (15–35) | p=0·492 | p=0·001 | p=0·010 | |
| Delivery | 7·21 (4·88–11) | 8·78 (5·95–13) | 15 (10–22) | p=0·479 | p=0·007 | p=0·046 | |
| Serotype Ib | |||||||
| Data available, n | 44 | 53 | 66 | .. | .. | .. | |
| Geometric mean antibody concentration (μg/mL) | |||||||
| Day 1 pre-vaccination | 0·51 (0·38–0·70) | 0·36 (0·27–0·48) | 0·40 (0·31–0·51) | p=0·104 | p=0·205 | p=0·652 | |
| Day 15 post-vaccination | 2·93 (1·73–4·95) | 3·50 (2·17–5·65) | 6·07 (3·98–9·26) | p=0·617 | p=0·035 | p=0·090 | |
| Day 31 post-vaccination | 2·62 (1·62–4·24) | 3·68 (2·38–5·70) | 5·35 (3·63–7·87) | p=0·300 | p=0·024 | p=0·209 | |
| Delivery | 2·12 (1·36–3·31) | 3·04 (2·03–4·56) | 3·84 (2·69–5·50) | p=0·236 | p=0·042 | p=0·392 | |
| Geometric mean ratio to day 1 | |||||||
| Day 15 | 6·87 (4·08–12) | 8·23 (5·12–13) | 14 (9·36–22) | p=0·611 | p=0·033 | p=0·089 | |
| Day 31 | 6·11 (3·79–9·85) | 8·70 (5·63–13) | 13 (8·56–19) | p=0·277 | p=0·021 | p=0·211 | |
| Delivery | 4·83 (3·10–7·52) | 7·34 (4·90–11) | 9·14 (6·38–13) | p=0·165 | p=0·029 | p=0·425 | |
| Serotype III | |||||||
| Data available, n | 53 | 55 | 70 | .. | .. | .. | |
| Geometric mean antibody concentration (μg/mL) | |||||||
| Day 1 pre-vaccination | 0·12 (0·09–0·17) | 0·10 (0·07–0·14) | 0·14 (0·10–0·18) | p=0·407 | p=0·572 | p=0·145 | |
| Day 15 post-vaccination | 1·24 (0·79–1·95) | 1·52 (0·97–2·36) | 5·90 (3·99–8·72) | p=0·528 | p<0·0001 | p<0·0001 | |
| Day 31 post-vaccination | 1·51 (0·97–2·35) | 1·31 (0·85–2·02) | 5·35 (3·66–7·83) | p=0·643 | p<0·0001 | p<0·0001 | |
| Delivery | 1·25 (0·81–1·94) | 1·07 (0·70–1·65) | 3·80 (2·61–5·55) | p=0·616 | p=0·0002 | p<0·0001 | |
| Geometric mean ratio to day 1 | |||||||
| Day 15 | 9·85 (6·25–16) | 12 (7·64–18) | 47 (32–70) | p=0·555 | p<0·0001 | p<0·0001 | |
| Day 31 | 12 (7·70–19) | 10 (6·62–16) | 43 (29–63) | p=0·599 | p<0·0001 | p<0·0001 | |
| Delivery | 9·99 (6·44–15) | 8·65 (5·65–13) | 30 (21–44) | p=0·638 | p=0·0002 | p<0·0001 | |
Data are geometric means (95% CI), unless otherwise stated. p values for pairwise comparisons are given in the last three columns (ANCOVA).